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The phosphoinositide 3-kinase (PI3K) pathway is frequently activated in cancer as a result
of genetic (e.g., amplifications, mutations, deletions) and epigenetic (e.g., methylation,
regulation by non-coding RNAs) aberrations targeting its key components. Several lines of
evidence demonstrate that tumors from different anatomical sites depend on the continued
activation of this pathway for the maintenance of their malignant phenotype.The PI3K path-
way therefore is an attractive candidate for therapeutic intervention, and inhibitors targeting
different components of this pathway are in various stages of clinical development. Bur-
geoning data suggest that the genomic features of a given tumor determine its response
to targeted small molecule inhibitors. Importantly, alterations of different components of
the PI3K pathway may result in distinct types of dependencies and response to specific
therapeutic agents. In this review, we will focus on the genomic determinants of response
to PI3K, dual PI3K/mechanistic target of rapamycin (mTOR), mTOR, and AKT inhibitors in
cancer identified in preclinical models and clinical trials to date, and the development of
molecular tools for the stratification of cancer patients.
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INTRODUCTION
The phosphoinositide 3-kinase (PI3K) signaling pathway regulates
numerous processes in the normal cell such as growth, prolifera-
tion, survival, motility, and metabolism (Engelman et al., 2006).
In human cancer, the PI3K pathway is one of the most frequently
activated signal transduction pathways, and its prominent role
is highlighted by the array of mechanisms targeting several of
its key components (Figure 1). Mutations and/or amplifications
of genes encoding receptor tyrosine kinases (RTKs) upstream
of class I PI3Ks (glossary box), including the human epidermal
growth factor receptors EGFR (ERBB1) and HER2 (ERBB2), of
the PI3K catalytic subunits p110α (PIK3CA) and p110β (PIK3CB),
the PI3K regulatory subunits p85α (PIK3R1) and p85β (PIK3R2),
the PI3K effector AKT (AKT1), and of the PI3K activator KRAS
are frequently observed in cancer [Catalog Of Somatic Mutations
In Cancer (COSMIC), http://www.sanger.ac.uk/cosmic; Forbes
et al., 2011], as is loss of function of the tumor suppressors
phosphatase and tensin homolog (PTEN) and inositol polyphos-
phate 4-phosphatase-II (INPP4B), negative regulators of PI3K
signaling, through mutations, deletions, or epigenetic mechanisms
(Gewinner et al., 2009; Fedele et al., 2010; Hollander et al., 2011).
Given that the PI3K pathway is frequently activated in can-
cers, that tumorigenesis and/or maintenance of the malignant
phenotype of different tumor types is driven by its continued
activation (Bader et al., 2005; Hollander et al., 2011), and that
kinases are amendable to pharmacological intervention, it is not
surprising that there has been great interest in the development
of allosteric and ATP-competitive small molecule inhibitors tar-
geting different components of this pathway downstream of RTKs
(Liu et al., 2009). These targeted agents include PI3K inhibitors,
either isoform specific [i.e., class I isoforms p110α, p110β, p110γ,
p110δ; (glossary box)] or pan-class I PI3K inhibitors, dual
PI3K/mechanistic target of rapamycin (mTOR) inhibitors, mTOR
inhibitors, and AKT inhibitors, which are all currently in various
stages of clinical development (Table 1).
Over the past years it has become apparent that irrespective
of the cancer type and small molecule inhibitor or antibody
used, kinase inhibitor response is limited to those tumors whose
proliferation and survival are reliant on the activation of the tar-
geted oncogenic kinase (Sharma and Settleman, 2007; Janne et al.,
2009). Bernard Weinstein coined the term “oncogene addiction”
to describe this phenomenon (Weinstein, 2002), which has impor-
tant implications for the targeting of kinases: given the incredibly
diverse repertoire of genetic and epigenetic aberrations observed
within a given cancer type, only the subset of tumors “addicted”
to the continued activation of the oncogenic kinase targeted
will prove vulnerable to the therapeutic intervention. Consis-
tent with this “oncogene addiction” concept, strong associations
between a tumor’s genotype and its response to small mole-
cule kinase inhibitors or antibodies targeting kinases have been
identified. For example, melanomas harboring BRAFV600E muta-
tions are selectively sensitive to the BRAF inhibitor Vemurafenib
(Flaherty et al., 2010), non-small cell lung cancers (NSCLCs)
harboring EGFR mutations to the EGFR inhibitors Gefitinib or
Erlotinib (Pallis et al., 2011), HER2 amplified breast and gastric
cancers to the HER2 targeting agents Trastuzumab or Lapatinib
(Stern, 2012), and KIT and PDGFRA mutant gastrointestinal
stromal tumors to Imanitib Mesylate and other small molecule
inhibitors targeting mutant KIT and PDGFRα (Antonescu, 2011).
Importantly, however, cancers harboring only wild-type copies of
www.frontiersin.org August 2012 | Volume 2 | Article 109 | 1
Weigelt and Downward PI3K pathway inhibitor response
FIGURE 1 | Class I PI3K signal transduction pathway. Components of
the class I PI3K signaling pathway (left) and of the mitogen-activated
protein kinase (MAPK) pathway (right) recurrently targeted by
genetic/epigenetic alterations in cancer are depicted with a red asterisk.
Several PI3K pathway inhibitors downstream of RTKs are currently being
tested in clinical trials (gray boxes). mTOR, mechanistic target of
rapamycin; mTORC, mTOR complex; PI3K, phosphoinositide 3-kinase;
PIP2, phosphatidylinositol 4,5-bisphosphate; PIP3, phosphatidylinositol
(3,4,5)-triphosphate; PTEN, phosphatase and tensin homolog; RTK,
receptor tyrosine kinase; TSC, tuberous sclerosis protein.
the genes mentioned above seem not to be sensitive to the same
agents.
As PI3K pathway inhibitors progress into trials focusing on their
clinical efficacy (Table 1), it is critical to identify their genomic
determinants of response and to select the patient population most
likely to benefit from treatment. In fact, it has been suggested to
incorporate predictive biomarkers throughout the clinical drug
development process from phase I studies onward in order to
enrich trials with patients more likely to respond to a given targeted
therapy and to increase the chances of drug registration (Carden
et al., 2010). For the guidance and prioritization of predictive bio-
marker candidates in early clinical trials, results derived from the
study of preclinical models are of importance.
In this review, we focus on the genomic determinants of
response to PI3K pathway inhibitors in cancer identified in preclin-
ical models and clinical trials to date, and discuss the challenges for
the development of molecular tools for the stratification of cancer
patients.
GENOMIC DETERMINANTS OF PI3K PATHWAY INHIBITOR
RESPONSE IN PRECLINICAL MODELS
The ease of therapeutic intervention using in vitro cell culture
and the wealth of data available on the mutational landscape of
known cancer genes in the most common cell lines obtainable
from commercial repositories have made cancer cell line panels
the model of choice for the preclinical study of drug response.
Furthermore, with the advent of methods for massively parallel
sequencing, it is now possible to identify the genomic determi-
nants of therapy response in in vitro models in a genome-wide
fashion (Barretina et al., 2012; Garnett et al., 2012). In general,
sensitivity or resistance of cancer cell lines to a given targeted
agent are determined by short-term treatment ranging from 48 to
120 h of cells grown on tissue culture plastic using several dilu-
tions of the inhibitor. At the endpoint, cell number or cell viability
is assessed and drug response reported as half-maximal inhibitory
concentration (IC50), or the concentration needed to reduce the
growth of treated cells to half that of untreated or vehicle treated
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Table 1 | Open clinical trials testing PI3K pathway inhibitors in cancer*.
Inhibitor name Company Target Clinical
trial phase
Cancer type
PAN-CLASS I PI3K INHIBITORS
BAY80-6946 Bayer Class I PI3K I Advanced solid cancers
ZSTK474 Zenyaku Kogyo Class I PI3K I Advanced solid cancers
GSK1059615 GlaxoSmithKline Class I PI3K I Terminated
BKM120 Novartis Class I PI3K I and II (Advanced) solid cancers; NSCLC, endometrial, prostate, breast,
colorectal, pancreatic, renal cell, GIST, melanoma, glioblastoma,
leukemia, SCCHN, TCC
GDC-0941 Roche/Genentech Class I PI3K I and II Solid cancers; breast, NSCLC, non-Hodgkin’s lymphoma
PX866 Oncothyreon Class I PI3K I and II Prostate, NSCLC, SCCHN, colorectal, glioblastoma
XL147 (SAR245408) Exelixis/Sanofi-Aventis Class I PI3K I and II Solid cancers; endometrial, ovarian, breast, NSCLC
ISOFORM SPECIFIC PI3K INHIBITORS
BYL719 Novartis p110α I Advanced solid cancers; SCCHN
GDC-0032 Roche/Genentech p110α I Solid cancers
INK-1117 Intellikine p110α I Advanced solid cancers
GSK2636771 GlaxoSmithKline p110β I/IIa Advanced solid cancers (PTEN deficient)
IPI-145 Infinity p110γ, p110δ I Advanced hematological malignancies
AMG319 Amgen p110δ I Relapsed or refractory lymphoid malignancies
CAL-101 (GS-1101) Gilead sciences p110δ I, II, and III Chronic lymphocytic leukemia, Hodgkin lymphoma, non-Hodgkin’s
lymphoma; mantle cell lymphoma, acute myeloid leukemia,
multiple myeloma
DUAL PI3K/mTOR INHIBITORS
DS-7423 Daiichi Sankyo PI3K/mTOR I Advanced solid cancers; colorectal, endometrial
GDC-0980 Roche/Genentech PI3K/mTOR I (Advanced) solid cancers; non-Hodgkin’s lymphoma, breast,
prostate, endometrial, renal cell
GSK2126458 GlaxoSmithKline PI3K/mTOR I Advanced solid cancers
PWT33597 Pathway Therapeutics PI3K/mTOR I Advanced solid cancers or malignant lymphoma
SF1126 Semafore PI3K/mTOR I Advanced solid cancers
BEZ235 Novartis PI3K/mTOR I and II Advanced solid cancers; renal cell, breast
BGT226 Novartis PI3K/mTOR I and II Completed (advanced solid cancers; breast)
PF-04691502 Pfizer PI3K/mTOR I and II Advanced solid cancers; breast, endometrial
PF-05212384 (PKI-587) Pfizer PI3K/mTOR I and II Advanced solid cancers; endometrial
XL765 (SAR245409) Exelixis/Sanofi-Aventis PI3K/mTOR I and II Advanced breast, gliomas, glioblastoma multiforme
mTOR KINASE INHIBITORS
AZD2014 AstraZeneca mTOR I Advanced solid cancers; breast
AZD8055 AstraZeneca mTOR I Recurrent glioma
INK-128 Intellikine mTOR I Advanced solid cancers; multiple myeloma, Waldenstrom
macroglobulinemia
OSI-027 Astellas Pharma mTOR I Advanced solid cancers; lymphoma
CC-223 Celgene Corporation mTOR I and II Advanced solid cancers; non-Hodgkin’s lymphoma, multiple
myeloma, NSCLC
ALLOSTERIC mTOR INHIBITORS (RAPAMYCIN ANALOGS)
Sirolimus (Rapamycin) Wyeth/Pfizer mTOR I, II, and III Advanced solid cancers; breast, liver, rectum, NSCLC, leukemias,
lymphomas, head and neck, pancreatic, ovarian, fallopian tube,
glioblastoma, fibromatosis
Everolimus** (RAD001) Novartis mTOR I, II, and III Solid cancers; leukemias, lymphomas, breast, bladder, head and
neck, kidney/renal cell, liver, gastric, thyroid, neuroendocrine
tumors, ovarian, fallopian tube, cervical, colorectal, brain and
central nervous system, prostate, endometrial, esophageal,
melanoma, NSCLC, SCLC, germ cell, soft tissue sarcoma,
osteosarcoma, nasopharyngeal, glioma, Waldenstrom’s
macroglobulinemia
(Continued)
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Table 1 | Continued
Inhibitor name Company Target Clinical
trial phase
Cancer type
Temsirolimus** (CCI-779) Wyeth/Pfizer mTOR I and II Advanced solid cancers; breast, endometrial, ovarian, prostate,
liver, kidney/renal cell, SCCHN, NSCLC, melanoma, sarcoma,
lymphomas, leukemia, brain and central nervous system, bladder,
urethral
Ridaforolimus (MK-8669) Merck/Ariad mTOR I Advanced solid cancers; endometrial, ovarian, breast, NSCLC,
renal cell, soft tissue sarcoma
AKT INHIBITORS (ATP-Competitive)
ARQ 092 ArQule/Daiichi Sankyo AKT I Advanced solid cancers
AZD5363 AstraZeneca AKT I Advanced solid cancers
GSK2141795 GlaxoSmithKline AKT I Completed/not recruiting (advanced solid cancers; lymphoma)
GDC-0068 Roche/Genentech AKT I and II Advanced solid cancers; prostate cancer
GSK2110183 GlaxoSmithKline AKT I and II Solid cancers, hematological malignancies, multiple myeloma,
Langerhans cell histiocytosis, chronic lymphocytic leukemia
ALLOSTERIC AKT INHIBITORS
MK-2206 Merck AKT I and II Advances solid cancers; breast, endometrial, ovarian, fallopian
tube, peritoneal, gastric, gastroesophageal junction, colorectal,
prostate, NSCLC, SCLC, melanoma, kidney, leukemias,
lymphomas, biliary, head and neck, liver, thymic, nasopharyngeal
*Data retrieved from http://clinicaltrials.gov and http://www.fda.gov/ (May 2012).
**Temsirolimus: approved for the treatment of advanced renal cell carcinoma; Everolimus: approved for the treatment of progressive neuroendocrine tumors of
pancreatic origin, for advanced renal cell carcinoma after failure of treatment with sunitinib or sorafenib, for renal angiomyolipoma and tuberous sclerosis complex,
and for subependymal giant cell astrocytoma associated with tuberous sclerosis.
GIST, gastrointestinal stromal tumor; NSCLC, non-small cell lung cancer; SCCHN, squamous cell carcinoma of the head and neck; SCLC, small cell lung cancer; TCC,
transitional cell carcinoma of the urothelium.
cells (GI50). In addition, xenograft studies in immunodeficient
mice injected with human cancer cell lines or human tumor tis-
sues, as well as transgenic mouse models have been employed to
assess anti-tumor activity of PI3K pathway inhibitors in vivo using
tumor growth, proliferation, apoptosis, and/or levels of pathway
activation state as read-out of treatment response.
Using these preclinical approaches, several groups attempted
to define genomic determinants of response to PI3K pathway
inhibitors. It should perhaps not come as a surprise that genetic
alterations leading to PI3K pathway activation, including PIK3CA
gain-of-function mutations and/or PTEN mutations/PTEN loss
of function and/or amplification of HER2, have been repeatedly
identified as predictors of response to these agents (Table 2).
However, tumor type-specific differences have been observed. For
example, in ovarian cancer cells both PIK3CA mutations and
PTEN deficiency have been reported to predict PI3K pathway
inhibitor response (Ihle et al., 2009; Di Nicolantonio et al., 2010;
Meuillet et al., 2010; Santiskulvong et al., 2011; Tanaka et al., 2011;
Meric-Bernstam et al., 2012), whereas in breast cancer the associ-
ations between PTEN loss of function and response are less clear
(She et al., 2008; Brachmann et al., 2009; Lehmann et al., 2011;
Sanchez et al., 2011; Tanaka et al., 2011; Weigelt et al., 2011), which
will be discussed in greater detail below.
Several studies provided evidence to suggest that cancer cells
harboring PIK3CA gain-of-function mutations are selectively sen-
sitive to inhibitors of different components of the PI3K pathway.
In breast cancer, cell culture, and/or xenograft models identified
PIK3CA mutations as determinant of response to PI3K inhibi-
tion (O’Brien et al., 2010; Sanchez et al., 2011), dual PI3K/mTOR
inhibition (Serra et al., 2008; Brachmann et al., 2009; Lehmann
et al., 2011; Sanchez et al., 2011), mTOR kinase inhibition (Weigelt
et al., 2011), allosteric mTOR inhibition (Sanchez et al., 2011;
Weigelt et al., 2011), and AKT inhibition (She et al., 2008; Meuillet
et al., 2010; Table 2). In one report, however, which assessed seven
estrogen receptor (ER)-positive breast cancer cell lines and their
response to the allosteric mTOR inhibitor Rapamycin (Sirolimus),
no correlation with PIK3CA mutation status but to some extent
with a PIK3CA mutation associated gene signature was found
(Loi et al., 2010). In vitro and xenograft models of breast can-
cer have also demonstrated that cells harboring amplification of
the RTK HER2 are dependent on PI3K pathway activation and
sensitive to its inhibition through targeting of PI3K (O’Brien
et al., 2010; Tanaka et al., 2011), dual PI3K/mTOR (Brachmann
et al., 2009), AKT (She et al., 2008), and mTOR kinase (Weigelt
et al., 2011). In fact, mTOR kinase inhibitors seem to lead to a
more effective decrease of PI3K pathway signaling than allosteric
mTOR inhibitors given that HER2 amplified breast cancer cells
in vitro have been found to be unresponsive to the rapamycin ana-
log (“rapalog”) Everolimus (RAD001; glossary box; Weigelt et al.,
2011). Whereas PIK3CA mutations and HER2 amplification have
been identified in the majority of preclinical breast cancer studies
as determinant of sensitivity to PI3K pathway inhibition down-
stream of RTKs, the correlation between PTEN deficiency and
response is less clear. In some studies, results were inconclusive as
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Table 2 | Genomic determinants of response to PI3K pathway inhibitors identified in preclinical cancer models.
Inhibitor (target) Cancer type Preclinical model Genomic determinant
of response
Reference
GDC-0941 (Class I PI3K) Breast Cell lines PIK3CA mutation O’Brien et al. (2010)
Cell line xenografts HER2 amplification
BEZ235 (PI3K/mTOR) Breast Cell lines PIK3CA mutation Serra et al. (2008)
Cell line xenografts
BEZ235 (PI3K/mTOR) Breast Cell lines PIK3CA mutation Brachmann et al. (2009)
Cell line xenografts HER2 amplification
BEZ235 (PI3K/mTOR) Breast Cell lines PIK3CA mutation
(PTEN deficiency)
Lehmann et al. (2011)
BKM120 (Class I PI3K),
BGT226 (PI3K/mTOR),
Everolimus (mTOR)
Breast Cell lines PIK3CA mutation Sanchez et al. (2011)
PP242 (mTOR kinase) Breast Cell lines PIK3CA mutation Weigelt et al. (2011)
Everolimus (mTOR) HER2 amplification
(only for PP242)
Rapamycin (mTOR) Breast Cell lines None (not PIK3CA
mutations)
Loi et al. (2010)
AKTi-1/2 (AKT) Breast Cell lines PIK3CA mutation She et al. (2008)
Cell line xenografts HER2 amplification
Everolimus (mTOR) Non-malignant breast Cell lines (isogenic) PIK3CA mutation
(knock-in)
Di Nicolantonio et al. (2010)
Temsirolimus (mTOR) Multiple myeloma Cell lines PTEN deficiency Shi et al. (2002)
Everolimus (mTOR) Glioblastoma multiforme Cell lines None (not PTEN
deficiency)
Yang et al. (2008)
Human tumor
xenografts
BEZ235 (PI3K/mTOR) Ovarian Cell lines PIK3CA mutation Santiskulvong et al. (2011)
PTEN deficiency
WAY-175, WAY-176
(Class I PI3K)
Various (breast, prostate, melanoma, lung,
colon)
Cell lines PIK3CA mutation Yu et al. (2008)
PX866 (PI3K) Various (non-small cell lung cancer, colon,
breast, pancreatic, prostate, ovarian,
multiple myeloma)
Cell line xenografts PIK3CA mutation
PTEN deficiency
Ihle et al. (2009)
CH5132799 (PI3K) Various (breast, ovarian, prostate,
endometrial)
Cell lines PIK3CA mutation Tanaka et al. (2011)
Cell line xenografts
Temsirolimus (mTOR) Various (glioblastoma, prostate) Cell lines PTEN deficiency Neshat et al. (2001)
Everolimus (mTOR) Various (prostate, glioblastoma, breast,
ovarian, cervical)
Cell lines PIK3CA mutation Di Nicolantonio et al. (2010)
PTEN deficiency
Rapamycin (mTOR) Various (neuroendocrine, cervical,
hepatocellular, melanoma, ovarian, colon,
breast, renal cell, glioblastoma, breast)
Cell lines PIK3CA mutation
PTEN deficiency
Meric-Bernstam et al. (2012)
PHT-427 (AKT/PDPK1) Various (pancreatic, prostate, ovarian,
breast, lung)
Cell line xenografts PIK3CA mutation Meuillet et al. (2010)
25 PI3K pathway
inhibitors (PI3K,
PI3K/mTOR, AKT)
Various (lung, colorectal, gastric, breast,
ovarian, brain, renal, melanoma, prostate)
Cell lines None (p-AKT levels) Dan et al. (2010)
A-443654 (AKT) Various (bladder, blood, bone, breast,
CNS, GI tract, kidney, lung, ovary,
pancreas, skin, soft tissue, thyroid, upper
aerodigestive, uterus)
Cell lines SMAD4 mutation Garnett et al. (2012);
(http://www.cancerrxgene.org/;
Release 2, July 2012)
AKT inhibitor VIII (AKT) Various (bladder, blood, bone, breast,
CNS, GI tract, kidney, liver, lung, ovary,
pancreas, prostate, skin, soft tissue,
thyroid, upper aerodigestive, uterus)
Cell lines PIK3CA mutation
ERBB2 mutation
Garnett et al. (2012);
(http://www.cancerrxgene.org/;
Release 2, July 2012)
(Continued)
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Table 2 | Continued
Inhibitor (target) Cancer type Preclinical model Genomic determinant
of response
Reference
MK-2206 (AKT) Various (bladder, blood, bone, breast,
CNS, GI tract, kidney, liver, lung, ovary,
pancreas, prostate, skin, soft tissue,
thyroid, upper aerodigestive, uterus)
Cell lines PTEN mutation Garnett et al. (2012);
(http://www.cancerrxgene.org/;
Release 2, July 2012)
AZD6482 (p110β) Various (bladder, blood, bone, breast,
CNS, GI tract, kidney, liver, lung, ovary,
pancreas, prostate, skin, soft tissue,
thyroid, upper aerodigestive, uterus)
Cell lines PTEN mutation
PIK3CA mutation
Garnett et al. (2012);
(http://www.cancerrxgene.org/;
Release 2, July 2012)
BEZ235 (PI3K/mTOR) Various (bladder, blood, bone, breast,
CNS, GI tract, kidney, liver, lung, ovary,
pancreas, prostate, skin, soft tissue,
thyroid, upper aerodigestive, uterus)
Cell lines CDKN2A mutation
NRAS mutation
Garnett et al. (2012);
(http://www.cancerrxgene.org/;
Release 2, July 2012)
Temsirolimus (mTOR) Various (bladder, blood, bone, breast,
CNS, GI tract, kidney, liver, lung, ovary,
pancreas, prostate, skin, soft tissue,
thyroid, upper aerodigestive, uterus)
Cell lines PTEN mutation Garnett et al. (2012);
(http://www.cancerrxgene.org/;
Release 2, July 2012)
GDC-0941 (Class I
PI3K), AZD8055 (mTOR
kinase), Rapamycin
(mTOR), JW-7-52-1
(mTOR)
Various (bladder, bone, breast, CNS, GI
tract, kidney, liver, lung, ovary, pancreas,
prostate, skin, soft tissue, thyroid, upper
aerodigestive, uterus)
Cell lines None (TET2 mutations
associated with
AZD8055 response,
however only 3/554 cell
lines were TET2
mutant)
Garnett et al. (2012);
(http://www.cancerrxgene.org/;
Release 2, July 2012)
CONFIRMATORY STUDIES USING ANIMAL MODELS
BEZ235 (PI3K/mTOR) Prostate and glioblastoma Cell line xenografts PTEN deficiency Maira et al. (2008)
Rapamycin (mTOR) Breast and pancreatic Cell line xenografts PIK3CA mutation Meric-Bernstam et al. (2012)
WYE-354 (mTOR
kinase)
Prostate and glioblastoma Cell line xenografts PTEN deficiency Yu et al. (2009)
BEZ235 (PI3K/mTOR) Lung PIK3CA H1047R
mouse model
PIK3CA H1047R
mutation
Engelman et al. (2008)
Rapamycin (mTOR),
API-2 (AKT)
Ovarian endometrioid adenocarcinoma Apcflox/flox;
Ptenflox/flox mouse
model
PTEN deficiency Wu et al. (2011)
CNS, central nervous system; GI, gastrointestinal.
only a subset of PTEN null breast cancer cell lines were sensitive
to PI3K pathway inhibition (She et al., 2008; Lehmann et al., 2011;
Sanchez et al., 2011), whilst others found PTEN deficient breast
cancer cells to be preferentially resistant to treatment with PI3K
(Tanaka et al., 2011), dual PI3K/mTOR (Brachmann et al., 2009),
mTOR kinase, and allosteric mTOR inhibitors (Weigelt et al.,
2011). These data are consistent with the notion that aberrations in
the different components of the PI3K pathway are not necessarily
equivalent in their biological impact and their potential to activate
the signaling pathway (Stemke-Hale et al., 2008; Vasudevan et al.,
2009; Dan et al., 2010). Moreover, these observations also sug-
gest that sensitivity of PTEN deficient breast cancer cells to PI3K
pathway inhibitors may be dependent on epistatic interactions
between PI3K pathway genes and genes from other signaling path-
ways such as the MAPK pathway, as well as the release of negative
feedback loops and the node targeted by pharmacologic inhibition
(Efeyan and Sabatini, 2010; Zhang and Yu, 2010). Recent work in
preclinical models has suggested that PTEN deficient cancers may
depend on p110β rather than p110α signaling (Jia et al., 2008; Wee
et al., 2008; Edgar et al., 2010; Ni et al., 2012), and a p110β isoform
specific inhibitor (GSK2636771) is currently being tested in a clin-
ical trial of PTEN deficient malignancies (NCT01458067). In fact,
as in different disease contexts selective targeting of specific p110
isoforms may be more beneficial and less toxic than pan-PI3K
inhibition (Jia et al., 2009; Vanhaesebroeck et al., 2010; Jamieson
et al., 2011; Tzenaki et al., 2012), also p110α, p110γ, and p110δ spe-
cific inhibitors are being assessed in clinical trials (Table 1). The
contribution of the p85 isoforms (glossary box) to PI3K inhibitor
response is however not yet fully understood. There is evidence to
suggest that different cancer types express different levels of p110
and p85 isoforms (Cortes et al., 2012; Tzenaki et al., 2012), which
may lead to tumor type-specific combinations of catalytic and
regulatory PI3K subunits. It remains to be determined whether
certain PI3K inhibitors show preferential activity against specific
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p110/p85 isoform combinations and whether distinct mutations
in the regulatory subunits PIK3R1 or PIK3R2 have an impact on
PI3K inhibitor response.
The general effect of PIK3CA gain-of-function mutations in
the sensitization to PI3K pathway inhibitors has been confirmed
in a mouse model with inducible expression of human onco-
genic p110α (i.e., p110α H1047R), where treatment of the p110α
H1047R driven lung adenocarcinomas with the dual PI3K/mTOR
inhibitor BEZ235 led to marked tumor regression (Engelman et al.,
2008). In xenografts derived from the breast cancer cell line MCF7
and the pancreatic carcinoid cell line BON, both harboring an
activating PIK3CA mutation, treatment with the allosteric mTOR
inhibitor Rapamycin (Sirolimus) was associated with a signifi-
cant decrease in tumor volume (Meric-Bernstam et al., 2012).
Moreover, using PIK3CA wild-type human breast immortalized
epithelial cells (hTERT-HME1) or non-malignant MCF10A breast
cells, knock-in of the E454K or H1047R PIK3CA mutant alle-
les sensitized non-transformed human breast cells to the rapalog
Everolimus (Di Nicolantonio et al., 2010).
Also when focusing on an array of tumor types rather than
on a single disease entity, PIK3CA mutant cell lines, or cell line
derived xenografts were found to be selectively sensitive to PI3K
pathway inhibition (Table 2). For example, analysis of xenografts
derived from pancreatic, prostate, ovarian, NSCLC, and ovarian
cancer cells revealed that those harboring PIK3CA mutations were
among the most sensitive to the AKT inhibitor PHT-427 (Meuil-
let et al., 2010). This observation has been validated in a large
panel of breast, ovarian, prostate, and endometrial cancer cells,
given that those with PIK3CA mutations were found to be signif-
icantly more sensitive to the PI3K inhibitor CH5132799 in vitro
than those without (Tanaka et al., 2011). Other studies assessing
mixed tumor type cell line panels, however, have identified both
activating PIK3CA mutations and PTEN loss of function as deter-
minant of PI3K pathway inhibitor response. This was observed
in a panel of breast, melanoma, lung, colon, prostate cancer cells
treated in vitro with the PI3K inhibitors WAY-175 and WAY-176
(Yu et al., 2008), in a panel of human lung, colon, breast, pancre-
atic, ovarian, and multiple myeloma cell line derived xenografts
treated with the PI3K inhibitor PX866 (Ihle et al., 2009), and in
cell line panels of various tumor types treated in vitro with the
allosteric mTOR inhibitors Everolimus (Di Nicolantonio et al.,
2010) or Rapamycin (Meric-Bernstam et al., 2012). In one study,
the evaluation of the in vitro efficacy of 25 PI3K pathway inhibitors
in a panel of 39 human cancer cell lines did not identify any genetic
determinant of sensitivity (Dan et al., 2010).
It is interesting to note that whilst loss of PTEN function
has been shown to be a strong activator of the PI3K pathway
as determined by levels of AKT phosphorylation (Stemke-Hale
et al., 2008), only a few studies identified PTEN mutations/PTEN
deficiency as a single genomic determinant of response to PI3K
pathway inhibitors. Murine PTEN deficient ovarian endometri-
oid adenocarcinomas arising in Apcflox/flox; Ptenflox/flox mice have
been shown to be sensitive to Rapamycin and the AKT inhibitor
API-2 (Wu et al., 2011). Also in a panel of multiple myeloma
(Shi et al., 2002), glioblastoma, and prostate cancer cell lines
(Neshat et al., 2001), PTEN deficiency was reported to be asso-
ciated with enhanced sensitivity to the allosteric mTOR inhibitor
Temsirolimus (CCI-779). Consistent with this result, the PTEN
null glioblastoma cell line U-87MG and the prostate cancer cell
line PC3 were found to be sensitive to Rapamycin in vitro (Di
Nicolantonio et al., 2010), and when grown as xenografts to the
dual PI3K/mTOR inhibitor BEZ235 (Maira et al., 2008) and the
ATP-competitive mTOR inhibitor WYE-354 (Yu et al., 2009). At
variance with these findings, PTEN loss of function was shown
to be a poor predictor of Everolimus response in a panel of 17
glioblastoma multiforme cell lines, and in human glioblastoma
xenograft models (Yang et al., 2008).
The data discussed above on the genomic determinants of PI3K
pathway inhibitor response identified in vitro are based on the
analysis of up to 60 cancer cell lines, which were selected based
on different criteria by independent investigators. Recently, two
large-scale studies subjected hundreds of cancer cell lines derived
from tumors stemming from different anatomical sites and tis-
sue types to transcriptomic profiling, copy number profiling, and
massively parallel sequencing. Owing to their unprecedented scale
and approach employed, these studies unraveled several associa-
tions between genetic aberrations and response to specific targeted
therapies (Barretina et al., 2012; Garnett et al., 2012). Garnett et al.
(2012) tested up to 714 cell lines for their response to 138 anti-
cancer agents including ten PI3K pathway inhibitors downstream
of RTKs (http://www.cancerrxgene.org/; Release 2, July 2012), and
observed that, in line with previous findings, cancer cells harbor-
ing mutations in PIK3CA and PTEN were sensitive to treatment
with the AKT inhibitor VIII and MK-2206, respectively. Of note,
also ERBB2 mutations were associated with AKT inhibitor VIII
response. Sensitivity to the AKT inhibitor A-443654 and the dual
PI3K/mTOR inhibitor BEZ235, however, was not determined by
PI3K pathway aberrations but by the presence of SMAD4 and
CDKN2A mutations, respectively (Table 2). In Garnett et al. (2012)
mutations in PTEN were associated with response to the mTOR
inhibitor Temsirolimus, and not only PTEN but also PIK3CA
mutations predicted response to the PI3K isoform specific p110β
inhibitor AZD6482 (http://www.cancerrxgene.org/; Release 2). On
the other hand, contrary to previous reports, no mutations predic-
tive of response to the PI3K inhibitor GDC-0941, the mTOR kinase
inhibitor AZD8055, and the mTOR inhibitors Rapamycin and JW-
7-52-1 were identified (http://www.cancerrxgene.org/; Release 2;
Garnett et al., 2012; Table 2).
Mutation analysis has already become part of the diagnostic
armamentarium for lung and colon cancers (Allegra et al., 2009;
Keedy et al., 2011), and is also likely to be implemented in the man-
agement of other tumor types. In fact, the potential determinants
of PI3K pathway inhibitor response identified in preclinical studies
may provide a rationale for the guidance of predictive biomark-
ers to be assessed in early clinical trials. It should be noted here
that in addition to genomic response predictors also non-genetic
predictors of PI3K inhibitor response have been put forward, yet
none of them has been fully validated. In breast cancer, a gene
expression signature predictive of in vitro sensitivity to the PI3K
inhibitor GDC-0941 (O’Brien et al., 2010), and a PIK3CA muta-
tion associated gene signature (PIK3CA-GS) derived from exon 20
PIK3CA mutations able to predict PIK3CA mutation status in pri-
mary breast cancers and predictive of Rapamycin response in vitro
have recently been described (Loi et al., 2010). In addition, several
www.frontiersin.org August 2012 | Volume 2 | Article 109 | 7
Weigelt and Downward PI3K pathway inhibitor response
groups found increased phosphorylated (p)-AKT baseline levels
as a read-out for PI3K pathway activation to be associated with its
therapeutic intervention (Noh et al., 2004;Yu et al., 2008; Dan et al.,
2010; Meric-Bernstam et al., 2012). Despite the potential utility of
these approaches, it should be mentioned that gene expression sig-
natures and immunohistochemical assessment of phosphorylated
proteins have proven challenging to implement in routine clinical
practice (Pinhel et al., 2010; Weigelt et al., 2012).
Although predictive markers of sensitivity to PI3K pathway
inhibitors, such as PIK3CA mutations, are of importance for treat-
ment tailoring, markers predictive of resistance may be useful.
In fact, tumors harboring a given therapeutic target not uncom-
monly display primary (i.e., de novo) resistance or develop resis-
tance over time (van der Heijden and Bernards, 2010; Turner
and Reis-Filho, 2012). In several studies discussed here assess-
ing determinants of single agent PI3K pathway inhibitor response,
KRAS mutations were found to be associated with resistance to
these targeted agents (Engelman et al., 2008; Brachmann et al.,
2009; Ihle et al., 2009; Dan et al., 2010; Meuillet et al., 2010; Gar-
nett et al., 2012), as were mutations in APC, BRAF, or MYCN
(http://www.cancerrxgene.org/; Garnett et al., 2012).
Finally, in addition to genetic alterations of components of
the PI3K pathway germline polymorphisms may affect response
of patients treated with targeted therapies. Ng et al. (2012) have
recently identified a common intronic deletion polymorphism of
the BIM gene that leads to the generation of an alternative spliced
BIM isoform lacking the BH3 domain, which is required for tyro-
sine kinase inhibitor induced apoptosis. This polymorphism was
shown to confer intrinsic resistance to RTK inhibitors in chronic
myeloid leukemia and EGFR mutated NSCLC cell lines (Ng et al.,
2012). It is plausible that this and other germline polymorphisms
may results in resistance to agents targeting the PI3K pathway.
Taken together, preclinical studies focusing on breast can-
cer only have repeatedly identified PIK3CA mutations and
HER2 amplifications as predictors of sensitivity to PI3K path-
way inhibitors. In other tumor types, however, the genotype-drug
response associations are less defined and PIK3CA mutations,
PTEN loss of function or both, or CDKN2A mutations have been
reported as determinants of response. Furthermore, the in vitro
and animal model studies revealed that in cancer cells other than
breast cancer, where MAPK pathway mutations are rare (COS-
MIC), KRAS mutations may confer resistance to single agent PI3K
pathway inhibitor treatment, as do mutations in BRAF, APC and
MYCN.
GENOMIC DETERMINANTS OF PI3K PATHWAY INHIBITOR
RESPONSE IN CLINICAL TRIALS
Rapamycin analogs (“rapalogs”; glossary box) were the first PI3K
pathway inhibitors to be tested in clinical trials for the treatment of
cancer, and Everolimus and Temsirolimus have been approved by
the US Food and Drug Administration (FDA) for the treatment of
advanced renal cell carcinoma (ARCC), and Everolimus has also
been approved for the treatment of progressive neuroendocrine
tumors of pancreatic origin and non-malignant kidney and brain
tumors (Table 1).
The determinants of mTOR inhibition in renal cell carcino-
mas may differ from those of other solid malignancies. In fact,
clear cell renal cell carcinomas rarely harbor mutations in PI3K
pathway components (COSMIC), however commonly show loss
of function of the tumor suppressor genes PTEN (Brenner et al.,
2002;Velickovic et al., 2002) or von Hippel Lindau (VHL), a critical
regulator of the hypoxic response (Kim and Kaelin, 2004; Linehan
et al., 2010). Clear cell renal cell cancer has been suggested to be a
cell metabolism, angiogenesis-dependent and hypoxia-driven dis-
ease, and its response to mTOR inhibition thought to stem from its
impact on proliferation and cell survival but also from the fact that
the hypoxia-inducible-factor 1-α (HIF1-α) is under translational
control of the mTOR complex 1 (mTORC1; glossary box; Thomas
et al., 2006; Linehan et al., 2010). Exploratory subgroup analysis
of the 209 patients from the Temsirolimus single agent arm of the
phase III global ARCC trial (Hudes et al., 2007) investigated PTEN
and HIF1-α protein expression levels by immunohistochemistry
(IHC) on formalin fixed paraffin embedded nephrectomy or core
biopsy derived tissues. Importantly, baseline PTEN or HIF1-α lev-
els were shown not to be associated with single agent Temsirolimus
response (Figlin et al., 2009; Table 3). Furthermore, in a retrospec-
tive subgroup analysis from a phase II clinical trial of ARCC (Atkins
et al., 2004) including 20 patients (Cho et al., 2007), carbonic anhy-
drase IX (CA9), p-AKT, and PTEN protein expression levels using
IHC or VHL mutation status were shown not to be significantly
associated with single agent Temsirolimus response. There was,
however, a significant positive association between higher p-rpS6
expression, a downstream effector of mTORC1 (Figure 1), and
clinical Temsirolimus response (Cho et al., 2007). It should be
noted that the analysis above was performed in a limited number
of patients and their statistical power to reveal the associations
should be taken into account.
The vast majority of completed to date trials testing PI3K
pathway inhibitors in tumor types other than renal cell carci-
noma also focused on rapalogs, but only few studies assessed
potential genomic predictors (Table 3). Based on the rationale
that PIK3CA mutations may predict response to PI3K pathway
inhibitors, breast, cervical, endometrial, and ovarian cancers were
sequenced for the presence of activating PIK3CA mutations and
treated with different allosteric mTOR inhibitors (i.e., rapalogs) or
the PI3K inhibitor PX866 either as single agent or combination in a
prospective phase I clinical trial. A partial response was observed in
30% of the 23 patients with tumors harboring a PIK3CA mutation
in contrast to 10% of 70 patients whose tumors were PIK3CA wild-
type (Janku et al., 2012), consistent with the preclinical observa-
tions. Interestingly,whilst in preclinical models mutations in KRAS
have been found to confer resistance to PI3K pathway inhibition, as
discussed above, in this trial 2/7 ovarian cancer patients with coex-
isting PIK3CA and KRAS or BRAF mutations responded to the
anti-PI3K pathway treatment (Janku et al., 2012). This finding may
be tumor type-specific, given that the same group had previously
described that colorectal cancers harboring simultaneous PIK3CA
and KRAS mutations were resistant to PI3K pathway inhibitor
treatment (Janku et al., 2011). A similar, but not statistically sig-
nificant, trend was observed in a retrospective subgroup analysis
of 43 patients with different tumor types but most frequently
colorectal cancer from phase I/II clinical study of single agent
Everolimus (Tabernero et al., 2008; Di Nicolantonio et al., 2010).
Patients whose tumors harbored PIK3CA mutations or PTEN loss
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of function were more likely to benefit from Everolimus, except in
presence of coexistent KRAS/BRAF mutations (Di Nicolantonio
et al., 2010). A high percentage of responders with PI3K path-
way aberrations as determined by PIK3CA mutations or PTEN
loss of function was also reported in a phase I trial of lipo-
somal Doxorubicin, Bevacizumab, and Temsirolimus (Moroney
et al., 2011). Taken together, these results suggest PI3KCA gain-
of-function mutations may predict sensitivity to PI3K pathway
inhibitors, whereas KRAS and BRAF mutations may lead to resis-
tance in some tumor types such as colorectal cancer. Importantly,
however, the data available demonstrate that PIK3CA activating
mutations are neither required nor sufficient for a tumor to be
sensitive to PI3K pathway inhibitors, and that a substantial pro-
portion of cases with PIK3CA activating mutations may be de novo
resistant to these agents.
Not only genomic predictors but also PI3K pathway activation
state as determined by expression levels of markers upstream of
mTORC1, such as p-AKT, or downstream of mTORC1, such as
p-S6K (Figure 1), have been shown to correlate with sensitivity to
allosteric mTOR inhibitors in breast cancer cell lines in vitro (Noh
et al., 2004; Meric-Bernstam et al., 2012). In fact, several clini-
cal trials testing rapalogs evaluated PI3K signaling biomarkers on
baseline tumor tissue by IHC rather than performing sequenc-
ing analysis. In a phase II study, high p-AKT levels on baseline
and on-treatment fine needle aspirations of tumors from patients
with neuroendocrine carcinoma (n= 17) assessed by reverse phase
protein arrays correlated with longer progression-free survival
(PFS; Meric-Bernstam et al., 2012). Moreover, in NSCLC patients
treated with Everolimus (n= 40), p-AKT levels at baseline deter-
mined by IHC were reported to be independent predictors of PFS
(Soria et al., 2009; Table 3). It should be noted, however, that
the authors emphasized that tissue fixation had large effects on
immunoreactivity when assessing phosphorylated proteins, which
may compound the implementation of this IHC predictive test in
clinical practice.
In a phase II trial, p-S6K levels assessed by IHC in base-
line glioblastoma multiforme samples were associated with sin-
gle agent Temsirolimus response (n= 44; Galanis et al., 2005).
Also in a small retrospective subgroup analysis of two phase
I/II clinical trials p-rpS6, downstream of p-S6K, was correlated
with early response of sarcomas to the rapalog Deforolimus (i.e.,
Ridaforolimus) alone or in combination with doxorubicin (n= 20;
Iwenofu et al., 2008). Not only expression levels of activated (i.e.,
phosphorylated) S6K/rpS6 have been found to correlate with
response to allosteric mTOR inhibitors, but in phase II study,
total S6K expression in baseline SCLC tumor tissue defined by
IHC was reported as a potential predictive biomarker for the ther-
apeutic benefit of Everolimus (n= 22; Tarhini et al., 2010). In
addition, higher baseline levels of p-mTOR itself assessed by IHC
predicted for a better response to Temsirolimus in patients with
neuroendocrine carcinoma in a phase II study (n= 35; Duran
et al., 2006).
Other, similarly powered phase II trials however did not identify
any correlates between potential biomarkers assessed in archival
tumor material using IHC and treatment response (Table 3). In
metastatic breast cancers, no association between p-AKT, PTEN,
CA9, ER, progesterone receptor or HER2 expression, and response
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to Everolimus was found (Ellard et al., 2009). In bone and soft
tissue sarcomas, an extended subgroup analysis (n≈ 80; Chawla
et al., 2012) did not confirm the previously published analysis
on 20 patients, which identified p-rpS6 levels as Ridaforolimus
response predictors (Iwenofu et al., 2008). In fact, neither the
potential biomarkers upstream of mTORC1, including PTEN,
p-AKT, FKBP21, or IGF-1R, nor downstream of mTORC1, p-
S6K, 4E-BP1, eIF4E, or p27kip1, were predictive of clinical benefit
response to Ridaforolimus (Chawla et al., 2012). Furthermore,
p-AKT, p-mTOR, p-4E-BP1, and cyclin D1 expression levels in
epithelial ovarian and peritoneal tumors were shown not to
be associated with partial/complete tumor responses to Tem-
sirolimus, however cyclin D1 expression seemed to correlate with
PFS ≥6 months (Behbakht et al., 2011).
The completed phase I/II clinical trials to date are to some
extent consistent with the preclinical observations in that tumors
harboring PIK3CA mutations may be more likely to respond to
PI3K pathway inhibitors. It is important to note, however, that not
all patients with tumors harboring PIK3CA mutations are sensi-
tive to PI3K pathway inhibitor treatment, and, on the other hand,
that also subsets of patients with wild-type PIK3CA/PTEN cancers
are responsive. The results from studies analyzing the activation
state of PI3K pathway components by IHC are variable and no
consistent determinant of response has been identified to date.
DEVELOPMENT OF MOLECULAR TOOLS FOR THE
STRATIFICATION OF CANCER PATIENTS
For the development of molecular markers for patient stratifica-
tion in clinical trials testing the efficacy of PI3K pathway inhibitors,
it is crucial to take into account the observations that in some
tumor types, either PIK3CA activating mutations or PTEN loss
of function are predictors of sensitivity, whereas in other tumor
types, both predict sensitivity to these agents (Table 2). These data
imply that the mutational repertoire and the epistatic interactions
between different components of the PI3K pathway may be distinct
in different tumor types, that genetic lesions in different compo-
nents of the pathway may not have the same functional effects in
different tumor types, and that a genetic determinant identified in
one cancer type may not necessarily be applicable to another. This
is perhaps best exemplified by BRAFV600E mutations, which are
predictive of response to Vemurafenib in melanoma, however col-
orectal cancer patients harboring oncogenic BRAFV600E mutations
derive limited if any benefit from this drug due to increased EGFR
expression (Prahallad et al., 2012). Likewise, the clinical trials dis-
cussed above provide evidence to suggest that ovarian cancers with
coexisting PIK3CA and MAPK pathway mutations may be sensi-
tive to PI3K pathway inhibition, whereas colorectal cancers har-
boring the same repertoire of mutations affecting these genes may
be resistant (Di Nicolantonio et al., 2010; Janku et al., 2011, 2012).
Results from preclinical studies performed have further sug-
gested that cancer cells harboring PIK3CA mutations might be
among the most sensitive to single agent PI3K pathway inhibitors.
These data were in part confirmed in the three clinical trials assess-
ing tumor PIK3CA mutational status (Di Nicolantonio et al., 2010;
Janku et al., 2011, 2012; Moroney et al., 2011). The predictive value
of the PTEN status is however less clear, as in some clinical trials an
association between PTEN deficiency and PI3K pathway inhibitor
response was found (Di Nicolantonio et al., 2010; Moroney et al.,
2011) but not in others (Ellard et al., 2009; Figlin et al., 2009;
Chawla et al., 2012). A similar picture is seen when expression
levels of phosphorylated proteins of the PI3K pathway are used
as a read-out of its activation state and determinant of response
(Table 3). IHC of phosphorylated proteins has proven challenging
(Soria et al., 2009; Pinhel et al., 2010) and also PTEN staining is not
routinely performed. Recent reports focused on the reproducibil-
ity of PTEN staining protocols and scoring (Sakr et al., 2010; Garg
et al., 2012), however guidelines for accurate PTEN testing and its
utility as predictive marker have yet to be established.
Early clinical trials often analyze archival tissue of the primary
tumor for the presence of specific mutations and the response
of the metastatic lesions are correlated with the mutational sta-
tus. Recent analyses of paired primary tumors and metastases
have revealed that there is a high level of discordance in PTEN
expression level and PIK3CA mutation status, which may influ-
ence patient selection and response to PI3K targeted therapies
(Dupont Jensen et al., 2011; Gonzalez-Angulo et al., 2011).
Despite the interest in the development of biomarkers for
patient selection in clinical trials testing PI3K pathway inhibitors,
none of the biomarkers tested so far is supported by level I evi-
dence. Importantly, however, one of the most exciting results of
allosteric mTOR inhibitors in the context of a clinical study was
the BOLERO-2 trial, where patients with ER-positive advanced
breast cancers resistant to aromatase inhibitors were randomized
to receive Exemestane (a non-steroidal aromatase inhibitor) plus
Everolimus or Exemestane plus Placebo (Baselga et al., 2012). The
rationale for this stemmed from preclinical observations that resis-
tance to endocrine therapy in breast cancer is associated with
activation of the PI3K pathway (Miller et al., 2011). Despite the
lack of a patient stratification biomarker, this trial demonstrated
that addition of Everolimus to Exemestane increased the median
PFS from 4.1 to 10.6 months (Baselga et al., 2012). Although a
substantial proportion of patients included in this trial may har-
bor PIK3CA activating mutations, given that they are more likely
to occur in ER-positive postmenopausal patients (Kalinsky et al.,
2009), other mechanisms resulting in PI3K pathway activation are
likely to play a role in resistance to endocrine therapy. The material
from this trial will constitute a unique resource to determine the
genomic and epigenomic determinants of sensitivity to concurrent
mTOR inhibition and endocrine treatment in breast cancer.
FUTURE PERSPECTIVES AND CHALLENGES
Despite the critical role of the PI3K pathway in cancer, the intro-
duction of single-agent PI3K pathway inhibitors into the clinic
may be challenging. In fact, of all PI3K pathway inhibitors dis-
cussed here, one of the most exciting targeted agents is the p110δ
inhibitor CAL-101, which has shown remarkable clinical activity
in certain hematological diseases including chronic lymphocytic
leukemia. Inhibition of p110δ is though to target both the malig-
nant B cells and the tumor microenvironment of chronic lymphoid
leukemia (Fruman and Rommel, 2011). The clinical trials per-
formed thus far using allosteric mTOR inhibitors as single agents
have seen some stable diseases and partial responses, however
by no means are these responses as dramatic as for example for
Vemurafenib in BRAF mutant melanoma (Flaherty et al., 2010).
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Based in the preclinical data, kinase inhibitors seem to target the
PI3K pathway more robustly and, in contrast to allosteric mTOR
inhibitors, also promote apoptotic effects in vitro and in vivo
(Brachmann et al., 2009; O’Brien et al., 2010; Weigelt et al., 2011).
Several feedback loops upon PI3K/AKT/mTOR inhibition have
been described, which amongst others lead to activation of the
MAPK signaling pathway or re-activation of the PI3K pathway
(reviewed in Carracedo and Pandolfi, 2008; Efeyan and Sabatini,
2010; Chandarlapaty, 2012; Laplante and Sabatini, 2012). These
feedbacks may play a role in the modest responses observed thus
far using single agent rapalogs, and for the optimal activity of PI3K
pathway inhibitors, co-administration with other agents may be
required.
Numerous clinical trials are currently testing the safety and
efficacy of combination PI3K pathway and MEK inhibitors in
advanced solid tumors to target both the driver and poten-
tial “escape” pathways. As discussed above, such combinatorial
approach has been successfully performed in breast cancer, where
the combination of an aromatase inhibitor with Everolimus led
to substantial improvement of PFS (Baselga et al., 2012). For the
identification of optimal combinations of PI3K pathway inhibitors
with other agents, Drosophila models may provide an effective
tool as these have been successfully employed for the identifica-
tion of agents with optimized pharmacological profiles (Das and
Cagan, 2010; Dar et al., 2012). For combinatorial treatments it
will be crucial to understand the activation of negative feedback
loops in the PI3K pathway and the cross-talk with other pathway
upon inhibition of its different components, and whether the feed-
back activation is dependent on specific epistatic interactions and
distinct in tumors from different anatomical sites.
Drug sensitivity and resistance are likely to constitute conver-
gent phenotypes, meaning that they may be driven by distinct
genetic aberrations in the same tumor type (Gerlinger and Swan-
ton, 2010; Turner and Reis-Filho, 2012; Weigelt et al., 2012; Yap
et al., 2012). It has become apparent from in vitro studies that
there are significant correlations between specific mutations and
treatment response, however the negative predictive value of these
mutations is often poor and not all sensitive cancers are identified
by single mutations/single gene panels. For example, O’Brien et al.
(2010) showed that in their cell line panel tested, PIK3CA muta-
tions and HER2 amplification showed excellent specificity (100
and 95%, respectively) and a high positive predictive value, but
relatively low sensitivity (∼30%) and a poor negative predictive
value as single markers in predicting drug responsiveness in the
cell line panel analyzed. Additional biomarkers will therefore be
required to identify all patients likely to respond to PI3K path-
way inhibitors. To date, the majority of studies have focused on
the analysis of PIK3CA mutations or PTEN deficiency as potential
determinants of PI3K pathway inhibitor response. However, also
activating mutations in other components of the pathway, such as
PIK3R1 (Jaiswal et al., 2009; Urick et al., 2011) or mTOR (Sato et al.,
2010; Hardt et al., 2011), or loss of function of TSC1/2 (COSMIC;
El-Hashemite et al., 2003; Sjodahl et al., 2011) or INPP4B (Gewin-
ner et al., 2009; Fedele et al., 2010) may play a role in PI3K pathway
inhibitor response. Furthermore, and as mentioned above, the
remarkable single agent activity of the PI3K isoform specific p110δ
inhibitor CAL-101 in chronic lymphocytic leukemia, a disease in
which PI3K pathway aberrations are relatively rare, emphasizes
that some targeted agents may be effective in vivo due to targeting
of tumor microenvironment interactions (Fruman and Rommel,
2011), which are unlikely to be uncovered using conventional
in vitro cell culture models or by the genomic characterization
of tumor cells only.
With the advent of massively parallel sequencing technologies,
several studies have documented intra-tumor genetic heterogene-
ity in solid cancers (reviewed in Turner and Reis-Filho, 2012;
Yap et al., 2012), and revealed that certain mutations, includ-
ing PIK3CA or PTEN mutations, may be only prevalent in a
subset of tumor cells in a given cancer (Gerlinger et al., 2012;
Shah et al., 2012). This has not only consequences for can-
cer drug resistance and the clinical utility of single agent tar-
geted therapy, but also questions whether potential biomarkers
assessed in a single biopsy will be representative of the entire
tumor.
Given the crucial role of the PI3K pathway in cancer, inhibitors
of its components are expected to be effective in subsets of many
different cancer types. Preclinical models have proven useful in
the identification of potential predictive biomarkers, however tis-
sue collection and assessment of biomarkers even in early clinical
trials are crucial, as is the development of robust and accurate
companion diagnostics. With the number of ongoing clinical tri-
als currently testing a wide gamut of PI3K pathway inhibitors,
our community should expect a wealth of data, which will help
improve therapeutic strategies for cancer patients.
GLOSSARY
PHOSPHOINOSITIDE 3-KINASE CLASSES
According to their structures and substrate specificities, PI3Ks are
divided into three classes, and class I PI3Ks are directly activated
by cell surface receptors (Liu et al., 2009). Class IA PI3Ks are
heterodimeric lipid kinases composed of a p110 catalytic sub-
unit (isoforms p110α, p110β, and p110δ, encoded by PIK3CA,
PIK3CB, and PIK3CD, respectively), and a regulatory subunit
(p85α and its splice variants p55α and p50α), p85β, and p55γ,
encoded by PIK3R1, PIK3R2, and PIK3R3, respectively); the class
IB PI3K is composed of the p110γ catalytic subunit, encoded by
PIK3CG, and the regulatory subunit p101, p84/p87 (Liu et al.,
2009; Vanhaesebroeck et al., 2010).
RAPAMYCIN AND RAPAMYCIN ANALOGS (“RAPALOGS”)
Mechanistic target of rapamycin is a serine/threonine kinase that
interacts with several proteins to form two distinct signaling com-
plexes called mTORC1 and mTORC2 (Laplante and Sabatini,
2012). Rapamycin and rapamycin analogs (“rapalogs”) bind the
FK506-binding protein (FKBP12) and together target preferen-
tially the mTORC1 by an allosteric mechanism, however pro-
longed treatment may also inhibit mTORC2 and disrupt its main
substrate AKT, possibly in a tissue-specific manner (Sarbassov
et al., 2006; Lamming et al., 2012).
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